CL2009000379A1 - Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer. - Google Patents

Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.

Info

Publication number: CL2009000379A1
Authority: CL; Chile
Prior art keywords: ligands; encodes; tie; receptor; fragment
Prior art date: 2008-02-20

Application number

CL2009000379A

Other languages

English (en)

Inventor

C Boone Thomas

D Oliner Jonathan

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-20

Filing date

2009-02-19

Publication date

2012-02-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40625974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-19 Application filed by Amgen Inc filed Critical Amgen Inc

2012-02-24 Publication of CL2009000379A1 publication Critical patent/CL2009000379A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2009000379A 2008-02-20 2009-02-19 Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer. CL2009000379A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US6663208P	2008-02-20	2008-02-20
US6194308P	2008-06-16	2008-06-16
US13936108P	2008-12-19	2008-12-19

Publications (1)

Publication Number	Publication Date
CL2009000379A1 true CL2009000379A1 (es)	2012-02-24

Family

ID=40625974

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2009000379A CL2009000379A1 (es)	2008-02-20	2009-02-19	Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.

Country Status (31)

Country	Link
US (5)	US8030025B2 (es)
EP (2)	EP2679599B1 (es)
JP (1)	JP5739163B2 (es)
KR (1)	KR101600639B1 (es)
CN (1)	CN102046657B (es)
AR (1)	AR070453A1 (es)
AU (1)	AU2009215804B2 (es)
BR (1)	BRPI0907530B1 (es)
CA (2)	CA2715324C (es)
CL (1)	CL2009000379A1 (es)
CO (1)	CO6290772A2 (es)
CR (1)	CR11658A (es)
CY (1)	CY1115321T1 (es)
DK (1)	DK2252632T3 (es)
EA (1)	EA022308B1 (es)
ES (2)	ES2453342T3 (es)
HR (1)	HRP20140341T1 (es)
IL (1)	IL207445A (es)
JO (1)	JO2913B1 (es)
MA (1)	MA32190B1 (es)
MX (1)	MX2010009185A (es)
MY (1)	MY156458A (es)
NZ (2)	NZ600112A (es)
PE (1)	PE20091571A1 (es)
PL (1)	PL2252632T3 (es)
PT (1)	PT2252632E (es)
RS (1)	RS53262B (es)
SI (1)	SI2252632T1 (es)
TW (1)	TWI433683B (es)
WO (1)	WO2009105269A1 (es)
ZA (1)	ZA201006173B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008346734A1 (en)	2008-01-03	2009-07-16	The Scripps Research Institute	Antibody targeting through a modular recognition domain
US8454960B2 (en)	2008-01-03	2013-06-04	The Scripps Research Institute	Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en)	2008-01-03	2013-11-05	The Scripps Research Institute	VEGF antibodies comprising modular recognition domains
US8557243B2 (en)	2008-01-03	2013-10-15	The Scripps Research Institute	EFGR antibodies comprising modular recognition domains
US8557242B2 (en)	2008-01-03	2013-10-15	The Scripps Research Institute	ERBB2 antibodies comprising modular recognition domains
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en)	2008-12-16	2012-03-13	Hoffmann-La Roche Inc.	Antibodies against human angiopoietin 2
DE102009053584A1 (de) *	2009-11-17	2011-05-19	Airbus Operations Gmbh	Trägersystem zum Aufnehmen von Behältern in einem Fahrzeug und Verwendung eines Trägersystems in einem Flugzeug
CA2798273A1 (en) *	2010-05-04	2011-11-10	Merrimack Pharmaceuticals, Inc.	Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2012009705A1 (en)	2010-07-15	2012-01-19	Zyngenia, Inc.	Ang-2 binding complexes and uses thereof
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US9512220B2 (en) *	2011-04-05	2016-12-06	Neopharm Co., Ltd.	Antibodies against angiopoietins 1 and 2, and their use
CA2837169C (en)	2011-05-24	2021-11-09	Zyngenia, Inc.	Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
US8691231B2 (en)	2011-06-03	2014-04-08	Merrimack Pharmaceuticals, Inc.	Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
LT2760471T (lt)	2011-09-30	2017-04-25	Dana-Farber Cancer Institute, Inc.	Terapiniai peptidai
US20130330745A1 (en) *	2011-12-20	2013-12-12	Abbott Japan Co. Ltd.	Methods of prognosis and diagnosis in sepsis
US20150044227A1 (en) *	2012-03-08	2015-02-12	Medimmune, Llc	Methods of treatment with angiopoietin-2 antibodies
WO2014009465A1 (en)	2012-07-13	2014-01-16	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
AU2014236867A1 (en)	2013-03-15	2015-09-24	Amgen Inc.	Methods and compositions relating to anti-CCR7 antigen binding proteins
EP3666886A1 (en)	2013-03-15	2020-06-17	Dana-Farber Cancer Institute, Inc.	Therapeutic peptides
US10293023B2 (en)	2013-03-15	2019-05-21	Children's Medical Center Corporation	Method of altering vascular permeability and uses thereof
CN105451767B (zh)	2013-03-15	2019-10-18	泽恩格尼亚股份有限公司	多价和单价多特异性复合物及其用途
US9828422B2 (en)	2013-07-29	2017-11-28	Samsung Electronics Co., Ltd.	Anti-Ang2 antibody
KR102146845B1 (ko)	2013-07-30	2020-08-21	삼성전자주식회사	앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
WO2015035215A1 (en)	2013-09-05	2015-03-12	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
KR102196450B1 (ko)	2013-09-17	2020-12-30	삼성전자주식회사	Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
WO2015085210A1 (en)	2013-12-06	2015-06-11	Dana-Farber Cancer Institute, Inc.	Therapeutic peptides
KR102206029B1 (ko) *	2014-01-27	2021-01-20	삼성전자주식회사	Ang-2에 특이적으로 결합하는 항체 및 그의 용도
EP3116903A2 (en)	2014-03-14	2017-01-18	Dana-Farber Cancer Institute, Inc.	Vaccine compositions and methods for restoring nkg2d pathway function against cancers
MA39599A (fr)	2014-05-14	2016-10-05	Merrimack Pharmaceuticals Inc	Dosage et administration d'agents thérapeutiques anti-egfr
JP6671298B2 (ja)	2014-05-16	2020-03-25	アムジェンインコーポレイテッド	Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
KR102349370B1 (ko)	2014-05-26	2022-01-10	삼성전자주식회사	인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
US9719135B2 (en) *	2014-07-03	2017-08-01	Mannin Research Inc.	Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016054114A1 (en) *	2014-09-29	2016-04-07	The Regents Of The University Of California	Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
JP2017532342A (ja) *	2014-10-17	2017-11-02	アムジエン・インコーポレーテツド	眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体
BR112017009790A2 (pt) *	2014-11-10	2017-12-19	Hoffmann La Roche	anticorpos direcionados ao anti-ang2 e métodos de uso
WO2016176427A1 (en)	2015-04-30	2016-11-03	Amgen Inc.	Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane
US20190004048A1 (en)	2015-06-26	2019-01-03	Amgen Inc.	Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
WO2018114728A1 (en)	2016-12-20	2018-06-28	F. Hoffmann-La Roche Ag	Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
US10537637B2 (en)	2017-01-05	2020-01-21	Gensun Biopharma Inc.	Checkpoint regulator antagonists
CA3056011A1 (en)	2017-03-14	2018-09-20	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
WO2019028012A2 (en)	2017-07-31	2019-02-07	Dana-Farber Cancer Institute, Inc.	METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
CA3093853A1 (en)	2018-03-26	2019-10-03	Amgen Inc.	Total afucosylated glycoforms of antibodies produced in cell culture
CN112638401B (zh)	2018-06-29	2024-11-19	璟尚生物制药公司	抗肿瘤拮抗剂
CN112930194B (zh)	2018-10-29	2024-08-09	豪夫迈·罗氏有限公司	抗体制剂
CN114340735B (zh)	2019-06-28	2024-11-12	璟尚生物制药公司	突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
KR102885180B1 (ko) *	2019-08-14	2025-11-14	주식회사 파멥신	항-tie2 항체 및 이의 용도
CN114450593A (zh)	2019-09-26	2022-05-06	美国安进公司	产生抗体组合物的方法
US20230273126A1 (en)	2020-06-04	2023-08-31	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
KR20230042502A (ko) *	2020-08-07	2023-03-28	난징 진스크립트 바이오테크 컴퍼니 리미티드	인간 안지오포이에틴-2 항체 및 그 용도
CN112126671B (zh) *	2020-08-18	2021-08-31	中山大学附属第五医院	无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
WO2022081824A1 (en)	2020-10-15	2022-04-21	Amgen Inc.	Relative unpaired glycans in antibody production methods
EP4237121A1 (en)	2020-10-29	2023-09-06	Industrial Polymers and Chemicals, Inc.	Air filter with pathogen monitoring and inactivation
JP7749696B2 (ja) *	2021-04-23	2025-10-06	ニオテスバイオインコーポレイテッド	アンジオポエチン－２に特異的に結合する抗体、またはその断片
WO2022256820A1 (en)	2021-06-03	2022-12-08	Gensun Biopharma Inc.	Multispecific antagonists
AR126089A1 (es)	2021-06-07	2023-09-13	Amgen Inc	Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
CN115947818B (zh) *	2022-10-25	2024-08-02	福州大学	一种血管生成素1突变体的设计及其制备方法和应用
WO2024220916A1 (en)	2023-04-20	2024-10-24	Amgen Inc.	Methods of determining relative unpaired glycan content
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (196)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en)	1983-11-01	1988-10-12	TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION	Pharmaceutical composition containing urokinase
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8925590D0 (en)	1989-11-13	1990-01-04	Central Blood Lab Authority	Monoclonal antibodies
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6713610B1 (en)	1990-01-12	2004-03-30	Raju Kucherlapati	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ES2284161T3 (es)	1990-01-12	2007-11-01	Amgen Fremont Inc.	Generacion de anticuerpos xenogenicos.
CA2089661C (en)	1990-08-29	2007-04-03	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
US5981726A (en)	1990-10-12	1999-11-09	The United States Of America As Represented By The Department Of Health And Human Services	Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US5608039A (en)	1990-10-12	1997-03-04	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Single chain B3 antibody fusion proteins and their uses
US5889157A (en)	1990-10-12	1999-03-30	The United States Of America As Represented By The Department Of Health And Human Services	Humanized B3 antibody fragments, fusion proteins, and uses thereof
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
ES2145004T3 (es)	1991-08-21	2000-07-01	Novartis Ag	Derivados de anticuerpos.
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5621083A (en)	1991-11-04	1997-04-15	Xoma Corporation	Immunotoxins comprising ribosome-inactivating proteins
US5837491A (en)	1991-11-04	1998-11-17	Xoma Corporation	Polynucleotides encoding gelonin sequences
US5885793A (en)	1991-12-02	1999-03-23	Medical Research Council	Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011794A1 (en)	1991-12-13	1993-06-24	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
US5955291A (en)	1992-01-09	1999-09-21	Alitalo; Kari	Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5811517A (en)	1992-01-27	1998-09-22	Icos Corporation	ICAM-related protein variants
US5837822A (en)	1992-01-27	1998-11-17	Icos Corporation	Humanized antibodies specific for ICAM related protein
WO1993015722A1 (en)	1992-02-07	1993-08-19	Syntex (Usa) Inc.	Controlled delivery of pharmaceuticals from preformed porous microparticles
PT574048E (pt)	1992-03-13	2002-12-31	Organon Teknika Bv	Peptidos e sequencias de acido nucleico relacionados com virus de epstein-barr
ES2252732T3 (es)	1992-05-26	2006-05-16	Immunex Corporation	Nueva citoquina que une cd30.
WO1994000469A1 (en)	1992-06-26	1994-01-06	Immunex Corporation	Novel tyrosine kinase
ATE381614T1 (de)	1992-07-24	2008-01-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6066718A (en)	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
JPH06153984A (ja)	1992-11-27	1994-06-03	Morinaga & Co Ltd	抗体および抗体ｃＤＮＡ
US5750106A (en)	1993-01-28	1998-05-12	Novartis Ag	Human monoclonal antibodies to cytomegalovirus
AU8143094A (en)	1993-11-12	1995-05-29	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	(tie-2), a novel receptor tyrosine kinase
US5879672A (en)	1994-10-07	1999-03-09	Regeneron Pharmaceuticals, Inc.	Tie-2 ligand 1
US5643755A (en)	1994-10-07	1997-07-01	Regeneron Pharmaceuticals Inc.	Nucleic acid encoding tie-2 ligand
AUPM379494A0 (en)	1994-02-10	1994-03-03	Ludwig Institute For Cancer Research	Immunointeractive molecules - ii
US5650490A (en)	1994-10-07	1997-07-22	Regeneron Pharmaceuticals, Inc.	Tie-2 ligand 2
US5814464A (en)	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
EP0796334A1 (en)	1994-10-28	1997-09-24	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Tumor-specific antibody fragments, fusion proteins, and uses thereof
US5783184A (en)	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
US20050287630A1 (en)	1995-04-27	2005-12-29	Abgenix, Inc.	Human antibodies derived from immunized xenomice
EP0822830B1 (en)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Human anti-IL-8 antibodies, derived from immunized xenomice
US5977322A (en)	1995-06-14	1999-11-02	The Regents Of The University Of California	High affinity human antibodies to tumor antigens
JP4436457B2 (ja)	1995-08-18	2010-03-24	モルフォシスアイピーゲーエムベーハー	蛋白質／（ポリ）ペプチドライブラリー
AU2527397A (en)	1996-03-13	1997-10-01	Protein Design Labs, Inc.	Fas ligand fusion proteins and their uses
IL118626A0 (en)	1996-06-11	1996-10-16	Xtl Biopharmaceuticals Limited	Anti HBV antibody
US6265564B1 (en)	1996-08-02	2001-07-24	Regeneron Pharmaceuticals, Inc.	Expressed ligand-vascular intercellular signalling molecule
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP0957166A4 (en)	1996-09-02	2004-12-15	Ko Okumura	HUMANIZED IMMUNOGLOBULIN SPECIFICALLY REACTING WITH A LIGAND Fas OR ONE OF ITS ACTIVE FRAGMENTS AND REGION FOR INDUCING APOPTOSIS BORN IN A LIGAND Fas
US5977319A (en)	1996-10-21	1999-11-02	Cambridge Antibody Technology Limited	Specific binding members for estradiol; materials and methods
WO1998018914A1 (en)	1996-10-31	1998-05-07	Duke University	Soluble tie2 receptor
US6133426A (en)	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
AU6542898A (en)	1997-03-05	1998-09-22	John Wayne Cancer Institute	Sialyl lewis antigens as targets for immunotherapy
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
US5972338A (en)	1997-09-19	1999-10-26	Genentech, Inc.	Tie ligands homologues
US6030831A (en)	1997-09-19	2000-02-29	Genetech, Inc.	Tie ligand homologues
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
GB9804121D0 (en)	1998-02-26	1998-04-22	Cancer Res Campaign Tech	Anti-angiogenic vaccines: materials and methods relating thereto
EP1071458A4 (en)	1998-03-13	2005-02-16	Dana Farber Cancer Inst Inc	HUMANIZED ANTIBODIES AND CORRESPONDING USES THEREOF
JP2000080100A (ja)	1998-06-17	2000-03-21	Japan Tobacco Inc	副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
US6387663B1 (en)	1998-07-31	2002-05-14	University Of Southern California	Targeting pharmaceutical agents to injured tissues
EP1123398B1 (en)	1998-10-16	2005-08-10	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Molecular pathogenicide mediated plant disease resistance
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US7112661B1 (en)	1998-10-30	2006-09-26	The Research Foundation Of State University Of New York	Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
IL137121A0 (en)	1998-10-30	2001-06-14	Miller Jonathan L	Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
EE05483B1 (et)	1998-12-23	2011-10-17	Pfizer, Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
WO2000057901A1 (en)	1999-03-26	2000-10-05	Regeneron Pharmaceuticals, Inc.	Modulation of vascular permeability by means of tie2 receptor activators
US6455035B1 (en)	1999-03-26	2002-09-24	Regeneron Pharmaceuticals, Inc.	Angiopoietins and methods of use thereof
WO2000073430A2 (de)	1999-05-27	2000-12-07	Max-Delbrück-Centrum für Molekulare Medizin	Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
WO2000075323A1 (en)	1999-06-07	2000-12-14	Immunex Corporation	Tek antagonists
ATE448246T1 (de)	1999-06-15	2009-11-15	Genentech Inc	Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
AU7676300A (en)	1999-10-12	2001-04-23	Cambridge Antibody Technology Limited	Human anti-adipocyte monoclonal antibodies and their use
JP2001206899A (ja)	1999-11-18	2001-07-31	Japan Tobacco Inc	ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2003518391A (ja)	1999-12-27	2003-06-10	クルセルホランドベーヴェー	エピトープに結合可能な蛋白質の変異体のライブラリーから発達した結合メンバーを選抜するために天然型エピトープを使用する方法
DE60130538T2 (de)	2000-02-03	2008-06-12	Millenium Pharmaceuticals, Inc., Cambridge	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
AU2001233114A1 (en)	2000-02-04	2001-08-14	Aeomica, Inc.	Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20020048763A1 (en)	2000-02-04	2002-04-25	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis
EP1130030A1 (en)	2000-03-02	2001-09-05	Roche Diagnostics Corporation	Human erythroid differentiation related factor
JP4019615B2 (ja) *	2000-03-10	2007-12-12	富士ゼロックス株式会社	光磁気素子、光磁気ヘッドおよび磁気ディスク装置
AU2001249760B2 (en)	2000-03-30	2005-04-21	Dyax Corp.	Mucin-1 specific binding members and methods of use thereof
US20010046496A1 (en)	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
EP1156062A1 (en)	2000-05-12	2001-11-21	GPC Biotech AG	Immunomodulatory human MHC class II antigen-binding peptides/proteins
KR20120053525A (ko)	2000-06-16	2012-05-25	캠브리지 안티바디 테크놀로지 리미티드	면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US20030166160A1 (en)	2001-09-06	2003-09-04	Hawley Stephen B.	Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
AU2001296494A1 (en)	2000-10-02	2002-04-15	Arizeke Pharmaceuticals, Inc.	Compositions and methods for the transport of biologically active agents across cellular barriers
WO2002059260A2 (en)	2000-11-17	2002-08-01	Hyseq, Inc.	Nucleic acids and polypeptides
DE10059930A1 (de)	2000-11-23	2002-05-29	Fischer Peter	Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002243539A1 (en)	2001-01-12	2002-07-24	Incyte Genomics, Inc.	Molecules for disease detection and treatment
ATE425187T1 (de)	2001-01-12	2009-03-15	Molecules Of Man Ab	Materialien und methoden zur behandlung von hepatitis c
WO2002074787A2 (en)	2001-02-02	2002-09-26	Arizeke Pharmaceuticals, Inc.	Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules
US20030054407A1 (en)	2001-04-17	2003-03-20	Peizhi Luo	Structure-based construction of human antibody library
EP2009027B1 (en)	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
WO2002094864A2 (en)	2001-05-25	2002-11-28	Genset S.A.	Human cdnas and proteins and uses thereof
JP4152315B2 (ja)	2001-06-28	2008-09-17	協和醗酵工業株式会社	線維芽細胞増殖因子−８に対するヒト化抗体および該抗体断片
JP2004538324A (ja)	2001-08-03	2004-12-24	メディカルリサーチカウンシル	細胞内抗体
US20050260195A1 (en)	2001-10-04	2005-11-24	Xtl Biopharmaceuticals Ltd.	Treatment of hepatitis B virus infection with human monoclonal antibodies
US7084257B2 (en)	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7658924B2 (en) *	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
US7138370B2 (en)	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
AR036833A1 (es)	2001-10-18	2004-10-06	Bayer Corp	Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular.
US7052695B2 (en)	2001-10-25	2006-05-30	Regeneron Pharmaceuticals, Inc.	Angiopoietins and methods of treating hypertension
US7226594B2 (en)	2001-11-07	2007-06-05	Agensys, Inc.	Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US7390885B2 (en)	2001-11-26	2008-06-24	Cell Matrix, Inc.	Humanized collagen antibodies and related methods
US7365167B2 (en)	2001-11-26	2008-04-29	Cell Matrix, Inc.	Humanized collagen antibodies and related methods
WO2003048328A2 (en)	2001-12-03	2003-06-12	Abgenix, Inc.	Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
SI1461428T1 (sl)	2001-12-03	2012-07-31	Alexion Pharma Inc	Postopek za proizvodnjo hibridnih protiteles
AR037756A1 (es)	2001-12-17	2004-12-01	Bayer Corp	Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
EP1467757B1 (en)	2001-12-28	2008-05-07	Amgen Fremont Inc.	Use of antibodies against the muc18 antigen
CA2471849A1 (en)	2001-12-28	2003-07-17	Abgenix, Inc.	Antibodies against the muc18 antigen
JP4246069B2 (ja)	2001-12-28	2009-04-02	協和発酵キリン株式会社	関節炎の治療薬
JP2005516965A (ja)	2001-12-28	2005-06-09	アブジェニックス・インコーポレーテッド	抗ｍｕｃ１８抗体を使用する方法
US7135174B2 (en)	2002-01-07	2006-11-14	Amgen Fremont, Inc.	Antibodies directed to PDGFD and uses thereof
US7241444B2 (en)	2002-01-18	2007-07-10	Pierre Fabre Medicament	Anti-IGF-IR antibodies and uses thereof
US7553485B2 (en)	2002-01-18	2009-06-30	Pierre Fabre Medicament	Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20040258699A1 (en)	2002-02-11	2004-12-23	Bowdish Katherine S.	Immunotherapeutics for biodefense
AR038568A1 (es)	2002-02-20	2005-01-19	Hoffmann La Roche	Anticuerpos anti-a beta y su uso
JP2005533486A (ja)	2002-02-20	2005-11-10	ダイアックス、コープ	Ｍｈｃ−ペプチド複合体結合リガンド
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US7193069B2 (en)	2002-03-22	2007-03-20	Research Association For Biotechnology	Full-length cDNA
CA2489004C (en)	2002-06-13	2013-01-08	Crucell Holland B.V.	Agonistic binding molecules to the human ox40 receptor
JP4660189B2 (ja)	2002-07-03	2011-03-30	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
DK2314629T4 (da)	2002-07-18	2023-02-06	Merus Nv	Rekombinant produktion af blandinger af antistoffer
US20040110933A1 (en)	2002-09-13	2004-06-10	Dyax Corporation	CD44-binding ligands
CA2499207A1 (en)	2002-09-16	2004-03-25	Abgenix, Inc.	Method for the treatment of nephritis using anti-pdgf-dd antibodies
JP2006501856A (ja)	2002-10-09	2006-01-19	インテグリジェン，インコーポレイテッド	組換え触媒ポリペプチドおよびその使用
US20040151724A1 (en)	2002-10-31	2004-08-05	Julia Coronella-Wood	Antibody fab fragments specific for breast cancer
AU2003284427A1 (en)	2002-11-22	2004-06-18	Chugai Seiyaku Kabushiki Kaisha	Antibody against lesion tissue
DE10256900A1 (de)	2002-11-29	2004-06-24	Nemod Immuntherapie Ag	Tumorspezifische Erkennungsmoleküle
WO2004050683A2 (en)	2002-12-02	2004-06-17	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
US20050058649A1 (en)	2002-12-02	2005-03-17	Landes Gregory M.	Antibodies directed to phospholipase A2 and uses thereof
AU2003299581A1 (en)	2002-12-02	2004-06-23	Abgenix, Inc.	Antibodies against drugs of abuse
US20050009136A1 (en)	2003-02-19	2005-01-13	Dyax Corporation	PAPP-A ligands
ES2557769T3 (es)	2003-03-19	2016-01-28	Amgen Fremont Inc.	Anticuerpos contra el antígeno del dominio de inmunoglobulina de células T y el dominio 1 de mucina (TIM-1) y usos de los mismos
DK1626992T3 (da)	2003-05-23	2010-09-20	Crucell Holland Bv	Produktion af rekombinant IgM i PER.C6-celler
TWI374893B (en)	2003-05-30	2012-10-21	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US7595379B2 (en)	2003-05-30	2009-09-29	Agensys, Inc.	Antibodies and related molecules that bind to PSCA proteins
KR20130083463A (ko)	2003-06-27	2013-07-22	암젠 프레몬트 인코포레이티드	상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
KR101206206B1 (ko)	2003-07-22	2012-11-29	크루셀 홀란드 비.브이.	사스-코로나바이러스에 대한 결합분자 및 그것의 용도
US7318925B2 (en)	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
BR0318454A (pt)	2003-08-08	2006-09-12	Abgenix Inc	anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
US7485297B2 (en)	2003-08-12	2009-02-03	Dyax Corp.	Method of inhibition of vascular development using an antibody
US7871610B2 (en)	2003-08-12	2011-01-18	Dyax Corp.	Antibodies to Tie1 ectodomain
WO2005019270A2 (en)	2003-08-14	2005-03-03	Dyax Corp.	Endotheliase-2 ligands
EP1508576A1 (en)	2003-08-20	2005-02-23	Crucell Holland B.V.	Efficient production of IgA in recombinant mammalian cells
EP2060270A3 (en)	2003-10-16	2009-12-09	Imclone LLC	Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
ES2333971T3 (es)	2003-11-04	2010-03-03	Novartis Vaccines And Diagnostics, Inc.	Anticuerpos monoclonales anti-cd40 antagonistas y procedimientos para su uso.
EP1684869B1 (en)	2003-11-04	2011-07-20	Novartis Vaccines and Diagnostics, Inc.	Methods of therapy for b cell-related cancers
JP4637749B2 (ja)	2003-11-11	2011-02-23	中外製薬株式会社	ヒト化抗ｃｄ４７抗体
EP1687336A2 (en)	2003-11-28	2006-08-09	AstraZeneca AB	Antibodies
US7612179B2 (en)	2003-11-28	2009-11-03	Astrazeneca Ab	antibodies binding to a C-terminal fragment of apoliopoprotein E
CA2548015A1 (en)	2003-12-05	2005-06-23	John R. Schreiber	Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse
TW200530269A (en)	2003-12-12	2005-09-16	Chugai Pharmaceutical Co Ltd	Anti-Mpl antibodies
US20050136055A1 (en)	2003-12-22	2005-06-23	Pfizer Inc	CD40 antibody formulation and methods
EA012872B1 (ru)	2004-01-09	2009-12-30	Пфайзер Инк.	АНТИТЕЛА ПРОТИВ MAdCAM
KR20140066259A (ko)	2004-02-06	2014-05-30	모르포시스 아게	항-ｃｄ３８ 인간 항체 및 그의 용도
TW200605906A (en)	2004-05-11	2006-02-16	Chugai Pharmaceutical Co Ltd	Remedy for thrombopenia
DK1749029T3 (da)	2004-05-27	2011-06-06	Crucell Holland Bv	Bindemolekyler, der kan neutralisere rabiesvirus, og anvendelser deraf
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
UA94019C2 (ru)	2004-07-09	2011-04-11	Чугаи Сейяку Кабусики Кайся	Антитело, которое специфически связывается с глипиканом 3 (gpc3)
AU2004321433B2 (en)	2004-07-14	2011-07-21	Greenovation Biotech Gmbh	N-glycosylated antibody
MX2007000644A (es)	2004-07-20	2007-03-28	Symphogen As	Anticuerpo policlonal recombinante anti-rhesus d y metodos de fabricacion.
EP1805222B1 (en)	2004-10-01	2011-02-02	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Antibodies directed to the mammalian eag1 ion channel protein
HRP20110859T1 (hr)	2004-12-21	2011-12-31	Medimmune Limited	Protutijela usmjerena na angiopoietin-2 i njihova upotreba
MY146381A (en) *	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
PE20071101A1 (es)	2005-08-31	2007-12-21	Amgen Inc	Polipeptidos y anticuerpos
US8359965B2 (en)	2007-09-17	2013-01-29	Oxford J Craig	Apparatus and method for broad spectrum radiation attenuation
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2009158432A2 (en) *	2008-06-27	2009-12-30	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
US9100245B1 (en)	2012-02-08	2015-08-04	Amazon Technologies, Inc.	Identifying protected media files
US9401875B2 (en)	2012-06-01	2016-07-26	Nippon Telegraph And Telephone Corporation	Packet transfer processing method and packet transfer processing device
US9306926B2 (en)	2013-03-15	2016-04-05	Brian A. Truong	User authentication using unique hidden identifiers
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof

2009
- 2009-02-10 JO JO200963A patent/JO2913B1/en active
- 2009-02-19 CL CL2009000379A patent/CL2009000379A1/es unknown
- 2009-02-19 PE PE2009000241A patent/PE20091571A1/es active IP Right Grant
- 2009-02-19 US US12/378,993 patent/US8030025B2/en active Active
- 2009-02-20 CA CA2715324A patent/CA2715324C/en active Active
- 2009-02-20 RS RS20140162A patent/RS53262B/sr unknown
- 2009-02-20 TW TW098105405A patent/TWI433683B/zh not_active IP Right Cessation
- 2009-02-20 SI SI200930856T patent/SI2252632T1/sl unknown
- 2009-02-20 DK DK09711869.9T patent/DK2252632T3/da active
- 2009-02-20 AU AU2009215804A patent/AU2009215804B2/en active Active
- 2009-02-20 HR HRP20140341AT patent/HRP20140341T1/hr unknown
- 2009-02-20 CA CA2844188A patent/CA2844188A1/en not_active Abandoned
- 2009-02-20 EP EP13185473.9A patent/EP2679599B1/en active Active
- 2009-02-20 CN CN200980114708.7A patent/CN102046657B/zh not_active Expired - Fee Related
- 2009-02-20 ES ES09711869.9T patent/ES2453342T3/es active Active
- 2009-02-20 KR KR1020107021162A patent/KR101600639B1/ko not_active Expired - Fee Related
- 2009-02-20 MY MYPI2010003790A patent/MY156458A/en unknown
- 2009-02-20 NZ NZ600112A patent/NZ600112A/xx not_active IP Right Cessation
- 2009-02-20 JP JP2010547650A patent/JP5739163B2/ja active Active
- 2009-02-20 PL PL09711869T patent/PL2252632T3/pl unknown
- 2009-02-20 EP EP09711869.9A patent/EP2252632B1/en active Active
- 2009-02-20 MX MX2010009185A patent/MX2010009185A/es active IP Right Grant
- 2009-02-20 ES ES13185473.9T patent/ES2660381T3/es active Active
- 2009-02-20 PT PT97118699T patent/PT2252632E/pt unknown
- 2009-02-20 AR ARP090100593A patent/AR070453A1/es active IP Right Grant
- 2009-02-20 NZ NZ587230A patent/NZ587230A/xx not_active IP Right Cessation
- 2009-02-20 WO PCT/US2009/001122 patent/WO2009105269A1/en not_active Ceased
- 2009-02-20 BR BRPI0907530-5A patent/BRPI0907530B1/pt not_active IP Right Cessation
- 2009-02-20 EA EA201001335A patent/EA022308B1/ru not_active IP Right Cessation
2010
- 2010-08-05 IL IL207445A patent/IL207445A/en active IP Right Grant
- 2010-08-30 CR CR11658A patent/CR11658A/es unknown
- 2010-08-30 ZA ZA2010/06173A patent/ZA201006173B/en unknown
- 2010-09-01 CO CO10107938A patent/CO6290772A2/es active IP Right Grant
- 2010-09-13 MA MA33172A patent/MA32190B1/fr unknown
2011
- 2011-07-29 US US13/194,854 patent/US8221749B2/en active Active
2012
- 2012-06-15 US US13/524,325 patent/US20120258122A1/en not_active Abandoned
2013
- 2013-08-26 US US13/975,748 patent/US20130336992A1/en not_active Abandoned
2014
- 2014-02-13 CY CY20141100111T patent/CY1115321T1/el unknown
2016
- 2016-12-02 US US15/367,955 patent/US10336820B2/en active Active

Also Published As

Publication number	Publication date
IL207445A0 (en)	2010-12-30
BRPI0907530B1 (pt)	2021-09-28
US8221749B2 (en)	2012-07-17
PL2252632T3 (pl)	2014-06-30
EP2252632B1 (en)	2014-01-15
IL207445A (en)	2015-09-24
MA32190B1 (fr)	2011-04-01
CY1115321T1 (el)	2017-01-04
CR11658A (es)	2010-10-11
WO2009105269A1 (en)	2009-08-27
EP2252632A1 (en)	2010-11-24
EA022308B1 (ru)	2015-12-30
CA2844188A1 (en)	2009-08-27
EP2679599A1 (en)	2014-01-01
JO2913B1 (en)	2015-09-15
US20170081398A1 (en)	2017-03-23
KR20100118143A (ko)	2010-11-04
AR070453A1 (es)	2010-04-07
HRP20140341T1 (hr)	2014-05-09
TW200940092A (en)	2009-10-01
NZ600112A (en)	2013-08-30
EP2679599B1 (en)	2018-01-03
NZ587230A (en)	2012-08-31
ES2453342T3 (es)	2014-04-07
CN102046657B (zh)	2014-04-09
CA2715324C (en)	2014-05-13
BRPI0907530A2 (pt)	2015-07-28
US20130336992A1 (en)	2013-12-19
MX2010009185A (es)	2011-02-23
PE20091571A1 (es)	2009-10-21
US8030025B2 (en)	2011-10-04
PT2252632E (pt)	2014-04-07
MY156458A (en)	2016-02-26
KR101600639B1 (ko)	2016-03-07
US20120034237A1 (en)	2012-02-09
ES2660381T3 (es)	2018-03-22
EA201001335A1 (ru)	2011-08-30
DK2252632T3 (da)	2014-04-07
TWI433683B (zh)	2014-04-11
AU2009215804A1 (en)	2009-08-27
HK1149023A1 (en)	2011-09-23
RS53262B (sr)	2014-08-29
SI2252632T1 (sl)	2014-03-31
JP5739163B2 (ja)	2015-06-24
US20090226447A1 (en)	2009-09-10
CN102046657A (zh)	2011-05-04
CA2715324A1 (en)	2009-08-27
AU2009215804B2 (en)	2013-04-18
JP2011525104A (ja)	2011-09-15
CO6290772A2 (es)	2011-06-20
US10336820B2 (en)	2019-07-02
ZA201006173B (en)	2011-10-26
US20120258122A1 (en)	2012-10-11

Publication	Publication Date	Title
CL2009000379A1 (es)	2012-02-24	Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013000669A1 (es)	2014-02-14	Agente de union a cd33 que se une al cd33 humano; molecula de adn que codifica la region variable de cadena pesada de un agente de union a cd33; vector de expresion; celula hospedante; metodo para reducir agente de unión a cd33; composicion farmaceutica; uso de la composicion farmaceutica para disminuir el numero de celulas que expresan el cd33 sobre su superficie.
CL2013001468A1 (es)	2014-03-21	Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2011000730A1 (es)	2012-02-03	Procedimiento de selección de anticuerpos anti-cxcr4 y anticuerpos seleccionados; ácido nucleico que codifica los anticuerpos; vector; célula huésped; procedimiento de producción; hibridoma que produce los anticuerpos; composición; uso de los anticuerpos seleccionados para preparar un medicamento para tratar cáncer.
CL2013000596A1 (es)	2014-02-14	Moleculas de union a vegf; molecula de acido nucleico que la codifica; celula hospedante; composicion farmaceutica; uso de la composicion para tratar efectos sobre la angiogenesis mediados por el vegf.
CL2013002062A1 (es)	2014-01-10	Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune.
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2012001547A1 (es)	2012-10-12	Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer.
CL2014000181A1 (es)	2014-07-25	Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).
CL2013000566A1 (es)	2014-01-24	Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2011002304A1 (es)	2012-04-09	Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.
CL2014001254A1 (es)	2014-10-10	Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
CL2015001353A1 (es)	2015-10-02	Molécula que contiene el dominio de fibronectina de tipo iii (fn3) biespecífico, donde el primer dominio se une al receptor del factor de crecimiento epidérmico (egrf) y el segundo al factor de crecimiento de hepatocitos (c-met); dominio de fn3; polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica que la comprende; y uso para tratar el cáncer.
CL2007002835A1 (es)	2008-05-30	Anticuerpo monoclonal especifico para el receptor cxcr4; acido nucleico que lo codifica; vector y celula que lo comprenden; metodo de produccion; inmunoconjugado y composicion que lo comprende; y su uso para tratar cancer, trastornos inflamatorios y
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
CL2014002750A1 (es)	2015-04-06	Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
BRPI0905733B8 (pt)	2021-05-25	composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2008002444A1 (es)	2009-09-04	Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2013001831A1 (es)	2013-11-08	Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
ECSP088750A (es)	2008-10-31	Métodos y composiciones para antagonismo de rage
CL2013002203A1 (es)	2013-12-06	Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea.